Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Meitheal Secures Licensing for XENLETA® to Expand Biopharmaceutical Portfolio
Details : Meitheal secured commercial rights in the U.S. to Xenleta (lefamulin acetate) through an exclusive license agreement with its parent company. It is indicated for the CABP in adults.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Details : Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
